サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451795

後天性希少血液疾患治療市場レポート：治療法、疾患適応症、流通チャネル、地域別、2024-2032

Acquired Orphan Blood Diseases Therapeutics Market Report by Therapy, Disease Indication, Distribution Channel, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
後天性希少血液疾患治療市場レポート：治療法、疾患適応症、流通チャネル、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

後天性希少血液疾患治療の世界市場規模は2023年に88億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに172億米ドルに達し、2024年から2032年の間に7.5%の成長率（CAGR）を示すと予測しています。個人における血液関連疾患の有病率の増加、政府の積極的な取り組み、世界のヘルスケアインフラの改善が、市場を牽引する主な要因のひとつです。

後天性希少血液疾患は、赤血球（RBC）の産生不能または血液中の赤血球の不足によって引き起こされる稀な血液疾患です。骨髄異形成症候群（MDS）、特発性血小板減少性紫斑病（ITP）、発作性夜間ヘモグロビン尿症（PNH）、骨髄線維症（MF）、真性多血症（PV）、後天性無顆粒球症など、数多くの疾患が含まれます。これらは骨髄の不適切な機能を引き起こし、血小板の数を減少させます。これらの疾患は、遺伝子組換え因子製剤、免疫グロブリン注入療法、活性化プロトロンビン複合体濃縮製剤、トロンボポエチン受容体作動薬など、いくつかの治療法で治療できるため、後天性希少血液疾患治療の需要は世界中で高まっています。

後天性希少血液疾患治療の市場動向：

現在、大衆の間で血液疾患とその治療法に関する認識が高まっており、世界的に個人の所得水準が上昇していることが、市場にプラスの影響を与える主な要因の1つとなっています。さらに、老年人口の増加による血液疾患治療薬の選択肢に対する需要の高まりが、市場の成長を強化しています。これに伴い、様々な国の行政機関や民間団体が、血液関連疾患の発生に関する認識を個人に広めることで血液疾患治療薬の採用を奨励しており、世界中で様々なヘルスケアイニシアチブを提供していることが、市場の成長を後押ししています。これとは別に、世界中の個人の間で様々な血液関連疾患の有病率が増加しているため、血液疾患治療薬の採用が増加しており、市場の見通しが明るくなっています。さらに、世界中のオンラインおよびオフラインの薬局店を通じて後天性希少血液疾患治療が広く入手可能であることも、市場の成長に寄与しています。これに加えて、世界のヘルスケアインフラの改善とともに、個人の間で個別化された医薬品に対する需要が高まっていることも、業界の投資家に有利な成長機会を提供しています。これに加えて、世界中の個人の間で費用対効果が高く質の高いケアソリューションに対する需要が高まっています。このことは、個人の間で蔓延する疾病を回避するための予防ケアやウェルネス・サービスの採用が増加していることと相まって、市場の成長を後押ししています。さらに、主要メーカーは鎌状赤血球貧血の小児患者向けにヒドロキシ尿素ベースの治療を導入しており、これが市場の成長を支えています。

本レポートで扱う主な質問

  • 後天性希少血液疾患治療の世界市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 後天性希少血液疾患治療の世界市場における促進要因、市場抑制要因、機会は何か？
  • それぞれの促進要因、抑制要因、機会が世界の後天性希少血液疾患治療市場に与える影響は？
  • 主要な地域市場は？
  • 後天性希少血液疾患治療市場で最も魅力的な国は？
  • 治療法別の市場内訳は？
  • 後天性希少血液疾患治療市場で最も魅力的な治療法はどれか？
  • 疾患適応症別の市場内訳は？
  • 後天性希少血液疾患治療市場で最も魅力的な疾患適応は？
  • 販売チャネル別の市場内訳は？
  • 後天性希少血液疾患治療市場で最も魅力的な流通チャネルはどこか？
  • 世界の後天性希少血液疾患治療市場の競合構造は？
  • 世界の後天性希少血液疾患治療市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界の後天性希少血液疾患治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療法別

  • リコンビナントファクター
    • 市場動向
    • 市場予測
  • 免疫グロブリン輸液療法
    • 市場動向
    • 市場予測
  • 活性化プロトロンビン複合体濃縮製剤
    • 市場動向
    • 市場予測
  • トロンボポエチン受容体作動薬
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：疾患適応症別

  • 後天性無顆粒球症
    • 市場動向
    • 市場予測
  • 後天性血友病
    • 市場動向
    • 市場予測
  • 後天性フォンウィルブランド症候群
    • 市場動向
    • 市場予測
  • 発作性夜間ヘモグロビン尿症（PNH）
    • 市場動向
    • 市場予測
  • 骨髄異形成症候群
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Alexion Pharmaceuticals Inc.（AstraZeneca plc）
    • Amgen Inc.
    • GSK plc
    • Novartis AG
    • Novo Nordisk A/S
    • Otsuka Pharmaceutical Co. Ltd.
    • Rigel Pharmaceuticals Inc.
    • Roche Holding AG
    • Sanofi
    • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Figure 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Therapy (in %), 2023
  • Figure 5: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Disease Indication (in %), 2023
  • Figure 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: North America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: North America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: United States: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: United States: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Canada: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Canada: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: China: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: China: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Japan: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Japan: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: India: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: India: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: South Korea: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: South Korea: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Australia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Australia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Europe: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Europe: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Germany: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Germany: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: France: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: France: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Italy: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Italy: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Spain: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Spain: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Russia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Russia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Latin America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Latin America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Brazil: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Brazil: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Mexico: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Mexico: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 84: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 86: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Value Chain Analysis
  • Figure 87: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Disease Indication (in Million US$), 2024-2032
  • Table 4: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Competitive Structure
目次
Product Code: SR112024A8217

The global acquired orphan blood diseases therapeutics market size reached US$ 8.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. The growing prevalence of blood-related disorders among individuals, favorable government initiatives, and improving healthcare infrastructure worldwide represent some of the key factors driving the market.

Acquired orphan blood diseases are rare blood conditions that are caused by an inability to produce red blood cells (RBCs) or their insufficiency in the blood. They comprise numerous diseases, such as myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), paroxysmal nocturnal hemoglobinuria (PNH), myelofibrosis (MF), polycythemia vera (PV), and acquired agranulocytosis. They can cause improper functioning of bone marrow and can decrease the number of platelets. As they can be treated through several therapies, such as recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, and thrombopoietin receptor agonists, the demand for acquired orphan blood disease therapeutics is rising across the globe.

Acquired Orphan Blood Diseases Therapeutics Market Trends:

At present, the increasing awareness about blood diseases and their treatment options among the masses, along with the inflating income level of individuals worldwide, represents one of the major factors influencing the market positively. Moreover, the rising demand for blood disease therapeutics options due to the increasing geriatric population is strengthening the growth of the market. In line with this, governing agencies and private organizations of various countries are encouraging the adoption of blood disease therapeutics by spreading awareness about the occurrence of blood-associated disorders among individuals and offering several healthcare initiatives around the world is impelling the growth of the market. Apart from this, the growing adoption of blood disease therapeutics due to the increasing prevalence of various blood-related disorders among individuals across the globe is offering a positive market outlook. Additionally, the wide availability of acquired orphan blood disease therapeutics drugs through online and offline pharmacy stores around the world is contributing to the growth of the market. Besides this, the increasing demand for personalized medicines among individuals, along with the improving healthcare infrastructure worldwide, is offering lucrative growth opportunities to industry investors. In addition to this, there is a rise in the demand for cost-effective and quality care solutions among individuals across the globe. This, coupled with the increasing adoption of preventative care and wellness services to avoid widespread disease among individuals, is bolstering the growth of the market. Furthermore, key manufacturers are introducing hydroxyurea-based treatment for pediatric patients with sickle cell anemia, which is supporting the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global acquired orphan blood diseases therapeutics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on therapy, disease indication, and distribution channel.

Therapy Insights:

Recombinant Factor

Immunoglobulin Infusion Therapy

Activated Prothrombin Complex Concentrate

Thrombopoietin Receptor Agonists

Others

The report has provided a detailed breakup and analysis of the acquired orphan blood diseases therapeutics market based on the therapy. This includes recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, thrombopoietin receptor agonists, and others.

Disease Indication Insights:

Acquired Agranulocytosis

Acquired Hemophilia

Acquired Von Willebrand Syndrome

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Myelodysplastic Syndrome

Others

A detailed breakup and analysis of the acquired orphan blood diseases therapeutics market based on the disease indication has also been provided in the report. This includes acquired agranulocytosis, acquired hemophilia, acquired von willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome, and others. According to the report, acquired hemophilia accounted for the largest market share.

Distribution Channel Insights:

Hospital Pharmacy

Retail Pharmacy

Others

A detailed breakup and analysis of the acquired orphan blood diseases therapeutics market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy, and others. According to the report, hospital pharmacy accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for acquired orphan blood diseases therapeutics. Some of the factors driving the North America acquired orphan blood diseases therapeutics market included the growing awareness about several treatment options, wide availability of therapeutic drugs, favorable government initiatives, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global acquired orphan blood diseases therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global acquired orphan blood diseases therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global acquired orphan blood diseases therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global acquired orphan blood diseases therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the therapy?
  • Which is the most attractive therapy in the acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the disease indication?
  • Which is the most attractive disease indication in the acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the acquired orphan blood diseases therapeutics market?
  • What is the competitive structure of the global acquired orphan blood diseases therapeutics market?
  • Who are the key players/companies in the global acquired orphan blood diseases therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acquired Orphan Blood Diseases Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Recombinant Factor
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunoglobulin Infusion Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Activated Prothrombin Complex Concentrate
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Thrombopoietin Receptor Agonists
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Disease Indication

  • 7.1 Acquired Agranulocytosis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Acquired Hemophilia
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Acquired Von Willebrand Syndrome
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Myelodysplastic Syndrome
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alexion Pharmaceuticals Inc. (AstraZeneca plc)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 GSK plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Novo Nordisk A/S
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Otsuka Pharmaceutical Co. Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Rigel Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Roche Holding AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Sanofi
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.